Journal: BMC Proceedings

Article Title: Implementation of a quality by design approach into cell line and process development for recombinant protein production

doi: 10.1186/1753-6561-9-S9-P79

Figure Lengend Snippet: A) Six clones derived from cell pool LPB were analyzed for fed-batch performance and protein quality attributes of the model IgG1 antibody . B) Effective clone selection as well as media and process optimization enables to match the N-glycosylation pattern of a reference protein. C) Scalability of the fed-batch process from shake flask to bioreactor scale has been demonstrated for different clones and is exemplarily shown for an IgG1 antibody.

Article Snippet: Bioreactor experiments in 200 L and 1000 L scale were performed at Rentschler Biotechnologie GmbH (Laupheim, Germany).

Techniques: Clone Assay, Derivative Assay, Selection

Journal: Current Opinion in Biotechnology

Article Title: Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail

doi: 10.1016/j.copbio.2022.102715

Figure Lengend Snippet: Scale comparison of key upstream performance measures. Stainless-steel Regeneron bioreactor pilot (500 L, blue), Regeneron Manufacturing (10 000 L, red), and Genentech Manufacturing (25 000 L, green) profiles for (A) pCO 2 and (B) titer for casirivimab and (C) pCO 2 and (D) titer for imdevimab. The manufacturing batches shown represent validation batches.

Article Snippet: To accommodate potential demand (need), the platform process was simultaneously transferred to both the typical intermediate-scale single-use bioreactor platform (2000 L) and, for casirivimab and imdevimab, the larger stainless-steel manufacturing scale (10 000 L) available at Regeneron.

Techniques: Comparison, Biomarker Discovery

Journal: Current Opinion in Biotechnology

Article Title: Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail

doi: 10.1016/j.copbio.2022.102715

Figure Lengend Snippet: Genentech dissolved oxygen manufacturing control strategy. Maintenance of the dissolved oxygen setpoint (30%; gray) required the addition of a constant 500 SLPM air sparge (blue) to the normal 25 000 L bioreactor strategy of increasing the air sparge to 500 SLPM (orange) and then replacing air with oxygen (green), maintaining a 500 SLPM total sparge (red) as part of the normal dissolved oxygen control system.

Article Snippet: To accommodate potential demand (need), the platform process was simultaneously transferred to both the typical intermediate-scale single-use bioreactor platform (2000 L) and, for casirivimab and imdevimab, the larger stainless-steel manufacturing scale (10 000 L) available at Regeneron.

Techniques: Control

Journal: Vaccine: X

Article Title: Development of an animal component free production process for Sabin inactivated polio vaccine

doi: 10.1016/j.jvacx.2022.100223

Figure Lengend Snippet: Flow diagram of the ACF production process of sIPV monovalent bulk. Pre-culture of cells was done in T -flasks and cell factories prior to start of the cell culture in bioreactors. After media exchange virus culture was started. Virus was harvested, clarified and concentrated prior to purification with two chromatography steps. For different viruses different resins were used. The diafiltration step prior to inactivation was performed for PV type 1 and 2. The associated buffer exchange was not required for PV type 3. Inactivation with formaldehyde was the final step to generate a monovalent bulk (indicated bulk circle). Trivalent sIPV was prepared by mixing inactivated monovalent bulks of PV 1, 2 and 3. A diagram for cIPV can be found in Thomassen et al. (2013) .

Article Snippet: Different lab-scale bioreactors were used (Applikon, Delft, The Netherlands or Sartorius, Göttingen, Germany).

Techniques: Cell Culture, Virus, Purification, Chromatography, Diafiltration Assay, Buffer Exchange

Journal: Vaccine: X

Article Title: Development of an animal component free production process for Sabin inactivated polio vaccine

doi: 10.1016/j.jvacx.2022.100223

Figure Lengend Snippet: Growth of Vero cells adherent to Cytodex 1 microcarriers (3 g/L) in VP-SFM during the first 96 h after inoculation at 10L scale in 15L bioreactors Panel A: Mean growth curve is given in blue, standard variation in green (n = 12). Points represent measurements of individual bioreactors. Panel B: photos showing representive pictures of Vero cells on microcarriers during the cell growth. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Different lab-scale bioreactors were used (Applikon, Delft, The Netherlands or Sartorius, Göttingen, Germany).

Techniques: